Ranbaxy Plans New JV in China (India)
This article was originally published in PharmAsia News
India's top pharmaceutical manufacturer Ranbaxy Laboratories has announced its intention to enter into a joint venture in China. According to representatives for Ranbaxy, it has approached two to three large Chinese manufacturers in search of the right match. If a deal goes through, Ranbaxy would work with these companies to turn out more active pharmaceutical ingredients (API) used in drug production. Currently, the majority of Ranbaxy's API is used for its own products. A China deal would allow Ranbaxy to improve its API capabilities. (Click here for more
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.